<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35959897</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study.</ArticleTitle><Pagination><StartPage>e60</StartPage><EndPage>e70</EndPage><MedlinePgn>e60-e70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac655</ELocationID><Abstract><AbstractText Label="BACKGROUND">The burden and duration of persistent symptoms after nonsevere coronavirus disease 2019 (COVID-19) remains uncertain. This study aimed to assess postinfection symptom trajectories in home-isolated COVID-19 cases compared with age- and time- matched seronegative controls, and investigate immunological correlates of long COVID.</AbstractText><AbstractText Label="METHODS">A prospective case-control study included home-isolated COVID-19 cases between February 28 and April 4, 2020, and followed for 12 (n = 233) to 18 (n = 149) months, and 189 age-matched severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naive controls. We collected clinical data at baseline, 6, 12, and 18 months postinfection, and blood samples at 2, 4, 6, and 12 months for analysis of SARS-CoV-2-specific humoral and cellular responses.</AbstractText><AbstractText Label="RESULTS">Overall, 46% (108/233) had persisting symptoms 12 months after COVID-19. Compared with controls, adult cases had a high risk of fatigue (27% excess risk, sex, and comorbidity adjusted odds ratio [aOR] 5.86; 95% confidence interval [CI], 3.27-10.5), memory problems (21% excess risk; aOR 7.42; CI, 3.51-15.67), concentration problems (20% excess risk; aOR 8.88; 95% CI, 3.88-20.35), and dyspnea (10% excess risk; aOR 2.66; 95% CI, 1.22-5.79). The prevalence of memory problems increased overall from 6 to 18 months (excess risk 11.5%; 95% CI, 1.5-21.5; P = .024) and among women (excess risk 18.7%; 95% CI, 4.4-32.9; P = .010). Longitudinal spike immunoglobulin G was significantly associated with dyspnea at 12 months. The spike-specific clonal CD4+ T-cell receptor &#x3b2; depth was significantly associated with both dyspnea and number of symptoms at 12 months.</AbstractText><AbstractText Label="CONCLUSIONS">This study documents a high burden of persisting symptoms after mild COVID-19 and suggests that infection induced SARS-CoV-2-specific immune responses may influence long-term symptoms.</AbstractText><CopyrightInformation>The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fjelltveit</LastName><ForeName>Elisabeth B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blomberg</LastName><ForeName>Bj&#xf8;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Advisory Unit for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwelker</LastName><ForeName>Kanika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onyango</LastName><ForeName>Therese B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brokstad</LastName><ForeName>Karl A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Safety, Chemistry and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elyanow</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf8;ndel</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research and Development, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohn</LastName><ForeName>Kristin G I</ForeName><Initials>KGI</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zg&#xfc;m&#xfc;&#x15f;</LastName><ForeName>T&#xfc;rk&#xfc;ler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Rebecca J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langeland</LastName><ForeName>Nina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0278-1616</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Advisory Unit for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Bergen COVID-19 Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>101563</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS CoV-2</Keyword><Keyword MajorTopicYN="N">T-cells</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. R.C. declares receipt of a research grant to the University of Bergen from Trond Mohn Stiftelse (TMS2020TMT05) and from the Helse-Vest to Haukeland University Hospital (F11628). N.L. declares receipt of a research grant from the Regional Health Authority of Western Norway and reports roles as Member of Faculty Board, NTNU, Trondheim, Norway, and as Member of the Board, Stavanger University Hospital, Stavanger, Norway. K.M. declares receipt of research grant from Helse-Vest (F12626). R.E. and I.M.K. declare employment and equity ownership with Adaptive Biotechnologies. The remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bredholt</LastName><ForeName>Geir</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lartey</LastName><ForeName>Sarah Larteley</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madsen</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olofsson</LastName><ForeName>Jan Stefan</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ljostveit</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xe6;vik</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xf8;yland</LastName><ForeName>Hanne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandnes</LastName><ForeName>Helene Heitmann</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ertesv&#xe5;g</LastName><ForeName>Nina Urke</ForeName><Initials>NU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vahokoski</LastName><ForeName>Juha</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bansal</LastName><ForeName>Amit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amdam</LastName><ForeName>H&#xe5;kon</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fomina</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linchausen</LastName><ForeName>Dagrun Waag</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauge</LastName><ForeName>Synn&#xf8;ve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corydon</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sund&#xf8;y</LastName><ForeName>Silje</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>8</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35959897</ArticleId><ArticleId IdType="pmc">PMC9384725</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac655</ArticleId><ArticleId IdType="pii">6663664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Prevention CfDCa . Post COVID Conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>
Excellence NIfHaC . COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available at: https://www.nice.org.uk/guidance/ng188/chapter/Recommendations.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Nanwani-Nanwani K, L&#xf3;pez-P&#xe9;rez L, Gim&#xe9;nez-Esparza C, et al. . Prevalence of post-intensive care syndrome in mechanically ventilated patients with COVID-19. Scientific Reports 2022; 12:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9105588</ArticleId><ArticleId IdType="pubmed">35562379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau AF, Minguet P, Colson C, et al. . Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic. Ann Intensive Care 2021; 11:118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319705</ArticleId><ArticleId IdType="pubmed">34324073</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli C, Zocchi C, Tassetti L, et al. . Factors associated with persistence of symptoms 1 year after COVID-19: a longitudinal, prospective phone-based interview follow-up cohort study. Eur J Int Med 2022; 97:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648678</ArticleId><ArticleId IdType="pubmed">34903448</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. . 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. The Lancet 2021; 398:747&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Baricich A, Patrucco F, et al. . Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. Sci Rep 2021; 11:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608998</ArticleId><ArticleId IdType="pubmed">34811387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang F, Shen Y, et al. . Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Network open 2021; 4:e2127403-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Bitna H, Kim SW, et al. . Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis 2022; 22:93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8793328</ArticleId><ArticleId IdType="pubmed">35086489</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Guida F, Polesel J, et al. . Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021; 11:1685&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9291310</ArticleId><ArticleId IdType="pubmed">34109765</ArticleId></ArticleIdList></Reference><Reference><Citation>Seessle J, Waterboer T, Hippchen T, et al. . Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis 2021; 16:e0256142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. . Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022; 10:863&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmsdal G, Hanusson KD, Kristiansen MF, et al. . Long COVID in the long run-23 months follow-up study of persistent symptoms. Open Forum Infect Dis 2022; 9:ofac270. Oxford University Press.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Network Open 2021; 4:e2128568-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg SK, Palm P, Nygaard U, et al. . Long COVID symptoms in SARS-CoV-2-positive children aged 0&#x2013;14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adoles Health 2022; 6:614&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221683</ArticleId><ArticleId IdType="pubmed">35752194</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA 2021; 325:2015&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis 2022; 22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8793328</ArticleId><ArticleId IdType="pubmed">35086489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Hallas J, Nielsen H, et al. . Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis 2021; 21:1373&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun 2021; 12:6571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med 2021; 27:1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Jernbom Falk A, Klingstrom J, et al. . SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PloS One 2022; 17:e0262169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754314</ArticleId><ArticleId IdType="pubmed">35020778</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, et al. . Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol 2021; 41:1490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al. . Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021; 36:109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwelker K, Zhou F, Blomberg B, et al. . Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: a case-ascertained study. Lancet Reg Health Eur 2021; 3:100014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009692</ArticleId><ArticleId IdType="pubmed">33871470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalder T, Berelowitz G, Pawlikowska T, et al. . Development of a fatigue scale. J Psychosom Res 1993; 37:147&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8463991</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieu MC, Bansal A, Madsen A, et al. . SARS-CoV-2-Specific neutralizing antibody responses in Norwegian health care workers after the first wave of COVID-19 pandemic: a prospective cohort study. J Infect Dis 2021; 223:589&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798943</ArticleId><ArticleId IdType="pubmed">33247924</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder TM, Gittelman RM, Klinger M, et al. . Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels. medRxiv 2020.Version 3. Preprint. NaN NaN [revised 2020 Sep 17]. doi: 10.1101/2020.07.31.20165647</Citation></Reference><Reference><Citation>Tan W, Lu Y, Zhang J, et al. . Viral kinetics and antibody responses in patients with COVID-19. medRxiv 2020. doi: 10.1101/2020.03.24.20042382</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.24.20042382</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS medicine 2021; 18:e1003773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun 2022; 13:1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, et al. . Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect 2021; 27:1507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplonek P, Fischinger S, Cizmeci D, et al. . mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity 2022; 55:355&#x2013;65 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733218</ArticleId><ArticleId IdType="pubmed">35090580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021; 12:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchese G, Fl&#xf6;el A. SARS-CoV-2 and Guillain-Barre syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones 2020; 25:731&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387880</ArticleId><ArticleId IdType="pubmed">32729001</ArticleId></ArticleIdList></Reference><Reference><Citation>Borsche M, Reichel D, Fellbrich A, et al. . Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19. Neurol Res Pract 2021; 3:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214919</ArticleId><ArticleId IdType="pubmed">34148546</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC, Oddi A, Peluso MJ, et al. . Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol 2022; 9:221&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, et al. . SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022; 604:697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>